Scherle Peggy 4

What Happened
Peggy Scherle, Chief Scientific Officer of Prelude Therapeutics (PRLD), was granted a derivative equity award on Feb 4, 2026 for 230,000 shares. The filing shows an acquisition at $0.00, indicating a stock option or similar equity award rather than an open‑market purchase. No cash was paid and no shares were sold.

Key Details

• Transaction date: 2026-02-04; Form 4 filed: 2026-02-05 (appears timely).
• Transaction type/code: A — Grant / award (derivative).
• Shares involved: 230,000 shares granted; reported price $0.00 (award/option).
• Vesting: 25% vests on Feb 4, 2027, then 1/48 of total shares vests monthly thereafter until fully vested, subject to continued service (see footnote).
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• No indication of a 10b5-1 plan, tax withholding, cashless exercise, or immediate sale in this filing.

Context
This was an equity award (option-style grant) with time-based vesting, not an open-market buy or sale. Such grants are common as compensation for executives and do not by themselves indicate intent to buy or sell stock in the market.